Global Ingredient Risk Index Botanical

Horse Chestnut

Aesculus hippocastanum (seed extract)

Also known as: horse chestnut seed extract, HCSE, aescin, escin, venastatin

25 მარ 2026

MODERATE RISK 4.0/10 How?

This ingredient is classified as unclassified risk (GIRI score: 4.0/10).

Known Safety Concerns

Raw/non-standardized product: esculin toxicity
Nephrotoxicity reported
Antiplatelet and anticoagulant interactions
Hypoglycemic effect -- drug interactions

Contraindications

Raw/non-standardized product: esculin toxicity
Nephrotoxicity reported

═══════════════════════════════════════════════════════════════════════ -->

Information not yet available for this ingredient profile.

Horse chestnut seed extract (HCSE) containing standardized aescin has strong evidence for chronic venous insufficiency. Raw horse chestnut seeds contain esculin, a toxic compound removed in standardized extracts. Nephrotoxicity has been reported.

Scientific Name: Aesculus hippocastanum (seed extract)

Information not yet available for this ingredient profile.

SETI Score 50/100

Risk Level High risk

Scientific Confidence Low

Evidence Strength Limited

Key Benefit Botanical

Key Safety Concern Raw/non-standardized product: esculin toxicity

Evidence Reviewed 10 PubMed studies

Scientific Confidence Low

Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100

Risk Level High risk

Evidence Strength Limited

Main Benefit Botanical

Main Safety Concern Raw/non-standardized product: esculin toxicity

Ingredient Horse Chestnut

Scientific name Aesculus hippocastanum (seed extract)

Scientific Evidence Overview

10 studies reviewed
0 high-quality studies (meta-analysis or RCT)
Main clinical benefit observed: Botanical
Evidence consistency: High consistency across studies (100%)

Safety Signals

Raw/non-standardized product: esculin toxicity
Nephrotoxicity reported
Antiplatelet and anticoagulant interactions
Hypoglycemic effect -- drug interactions

Evidence Strength Limited

Final Scientific Assessment

The available scientific evidence for Horse Chestnut indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Horse Chestnut

Evidence reviewed 10 peer-reviewed studies (last 10 years)

Scientific name Aesculus hippocastanum (seed extract)

50 /100

Total SETI Score

High risk

Evidence quality	10/40
Evidence consistency	20/20
Safety signals	0/20
Study recency	10/10
Evidence transparency	10/10

Evidence Summary

10 studies reviewed
0 high-quality studies (meta-analysis or systematic review)
0 studies identified benefits or no safety concern (GREEN)
10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 25 მარ 2026, 22:39

Evidence Distribution

10 Other / unclassified

Observational / other LOW evidence YELLOW
Modulation of Wnt/u03b2-Catenin Pathway by Aesculus hippocastanum Extract Enhances Temozolomide Sensitivity in Glioblastoma Cells. ↗

PMID 41693444 ↗

Journal J Cell Mol Med

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41693444/

Scuderi SA et al.. Modulation of Wnt/u03b2-Catenin Pathway by Aesculus hippocastanum Extract Enhances Temozolomide Sensitivity in Glioblastoma Cells.. J Cell Mol Med. 2026. PMID:41693444.
Observational / other LOW evidence YELLOW
Annual Dynamics of Mycobiota in Symptomatic Century-Old Trees of Aesculus hippocastanum, Fagus sylvatica, Populus alba, and Quercus robur. ↗

PMID 41590462 ↗

Journal J Fungi (Basel)

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41590462/

Spetik M et al.. Annual Dynamics of Mycobiota in Symptomatic Century-Old Trees of Aesculus hippocastanum, Fagus sylvatica, Populus alba, and Quercus robur.. J Fungi (Basel). 2026. PMID:41590462.
Observational / other LOW evidence YELLOW
Latvian herbal medicines under the infrared lens: An FTIR-ATR dataset. ↗

PMID 41510503 ↗

Journal Data Brief

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41510503/

Vu012btoliu0146a UL et al.. Latvian herbal medicines under the infrared lens: An FTIR-ATR dataset.. Data Brief. 2026. PMID:41510503.
Observational / other LOW evidence YELLOW
Aesculus hippocastanum Extract Exerts Neuroprotective Effects in an MPP(+)-Induced Parkinson's Disease Model via PPARu03b3 Activation. ↗

PMID 41492840 ↗

Journal J Cell Mol Med

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41492840/

Scuderi SA et al.. Aesculus hippocastanum Extract Exerts Neuroprotective Effects in an MPP(+)-Induced Parkinson's Disease Model via PPARu03b3 Activation.. J Cell Mol Med. 2026. PMID:41492840.
Observational / other LOW evidence YELLOW
Foliar Illumination Affects the Severity of Cameraria ohridella Damage Among Horse Chestnut Species. ↗

PMID 41515031 ↗

Journal Plants (Basel)

Year 2025

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41515031/

Bogoutdinova LR et al.. Foliar Illumination Affects the Severity of Cameraria ohridella Damage Among Horse Chestnut Species.. Plants (Basel). 2025. PMID:41515031.
Observational / other LOW evidence YELLOW
Delphi Consensus on the Role of Venoactive Nutraceuticals in the Management of Chronic Venous Disease: A Position Statement of the Italian Society… ↗

PMID 41470775 ↗

Journal Nutrients

Year 2025

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41470775/

Buso G et al.. Delphi Consensus on the Role of Venoactive Nutraceuticals in the Management of Chronic Venous Disease: A Position Statement of the Italian Society of Angiology and Vascular Medicine (SIAPAV).. Nutrients. 2025. PMID:41470775.
Observational / other LOW evidence YELLOW
Exfoliated Graphite as a Solid Sorbent in Ultrasound-Assisted Dispersive Micro-Solid-Phase Extraction for Determination of Chromium and Vanadium in Herbs. ↗

PMID 41376013 ↗

Journal Foods

Year 2025

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41376013/

Osiu0144ska M et al.. Exfoliated Graphite as a Solid Sorbent in Ultrasound-Assisted Dispersive Micro-Solid-Phase Extraction for Determination of Chromium and Vanadium in Herbs.. Foods. 2025. PMID:41376013.
Observational / other LOW evidence YELLOW
Extraction-Dependent Antioxidant Activity of Red Horse Chestnut (Aesculus u00d7 carnea, Family Sapindaceae) Plant Parts. ↗

PMID 41375147 ↗

Journal Molecules

Year 2025

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41375147/

Florkowska K et al.. Extraction-Dependent Antioxidant Activity of Red Horse Chestnut (Aesculus u00d7 carnea, Family Sapindaceae) Plant Parts.. Molecules. 2025. PMID:41375147.
Observational / other LOW evidence YELLOW
Antiradical and Antioxidant Activity and Stimulation of Pancreatic Lipase by Extracts Obtained from Saponin-Rich Raw Materials: Experimental and In Silico Study. ↗

PMID 41226295 ↗

Journal Int J Mol Sci

Year 2025

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41226295/

Sroka Z et al.. Antiradical and Antioxidant Activity and Stimulation of Pancreatic Lipase by Extracts Obtained from Saponin-Rich Raw Materials: Experimental and In Silico Study.. Int J Mol Sci. 2025. PMID:41226295.
Observational / other LOW evidence YELLOW
Multidisciplinary Bioanalytical Approach to Assess the Anti-Aging Properties of Flower Petals-A Promising Sustainable Cosmetic Ingredient. ↗

PMID 41012020 ↗

Journal Plants (Basel)

Year 2025

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41012020/

Ivkoviu0107 u0110 et al.. Multidisciplinary Bioanalytical Approach to Assess the Anti-Aging Properties of Flower Petals-A Promising Sustainable Cosmetic Ingredient.. Plants (Basel). 2025. PMID:41012020.

Q × L × D × S × 10 = 4.0 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

Benefit

Risk

50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 4.0 / 10

Final GIRI Score for Horse Chestnut. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.

MODERATE RISK 4.0/10

Based on available regulatory signals and scientific evidence, this ingredient presents a moderate safety concern. Caution is advised, particularly at high doses or in sensitive populations.

LOW
0–3.0

MODERATE
3.0–5.5

HIGH
5.5–7.5

CRITICAL
7.5–10

4.0

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Moderate classification for Horse Chestnut

A score of 4.0 places this ingredient in the Moderate band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

0 approved references.

Limited — mostly case reports or animal studies (Level 4–5).

Neutral or mixed — benefit and risk signals roughly balanced.

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

Level	Score	Meaning
LOW	0.0 – 2.9	Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE	3.0 – 5.4	Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH	5.5 – 7.4	Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL	7.5 – 10	Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

Horse Chestnut

Safety Profile

Known Safety Concerns

Contraindications

Interactions

Evidence and Scientific Findings

Ingredient Overview

Biological and Chemical Classification

Mechanism of Action

Clinical Evidence of Effectiveness

Pharmacokinetics

Recommended Dosage

SETI — Scientific Evidence Transparency Index

Executive Summary — Ingredient Assessment

Evidence Summary

Evidence Policy

Evidence Distribution

Score Transparency

Risk Level Classification

What drove the Moderate classification for Horse Chestnut

ბოლო სიახლეები

500მლ პლასტმასის წყლის ბოთლები: ფარული საზოგადოებრივი ჯანმრთელობის რისკები

სკოლამდელი განათლება – მნიშვნელობა და გამოწვევები

ბავშვის უფლებები სკოლაში

პოპულარული ამბები

საუკეთესო ფილმები კულინარიის მოყვარულებისთვის

როგორ იყენებენ ახალგაზრდები ხელოვნურ ინტელექტს – სტუდენტების ხმა

კატეგორიები

ჩვენ შესახებ

გამოგვყევი სოციალურ ქსელებში